Unlocking the Code of Hematopoietic Aging: Scientists Identify Novel Target to Reverse Immune Decline
Release time:
2026-07-17
Chronic inflammation and bodily aging have long been viewed as irreversible processes. However, a landmark study published in the top-tier immunology journal Immunityprovides a new molecular key to reversing this trajectory. A team led by Professor Yi Zhang at Harvard Medical School and Boston Children’s Hospital has discovered that activating a critical signaling axis known as IL-4–FLT3–STAT6 can successfully correct hematopoietic imbalances caused by aging and inflammation, effectively rejuvenating the immune systems of aged mice.
Breaking the Vicious Cycle: Targeting “Myeloid Bias”
With advancing age or under chronic inflammatory conditions, the body’s “hematopoietic factory”—hematopoietic stem and progenitor cells (HSPCs) in the bone marrow—gradually deviates from its normal production track. Instead of generating diverse blood lineages in a balanced manner, HSPCs increasingly churn out myeloid cells (such as granulocytes and monocytes), while markedly reducing the output of lymphoid cells (such as T and B cells), which mediate adaptive immunity. This phenomenon, termed “myeloid bias,” weakens immune defenses and further fuels systemic inflammation, creating a vicious cycle that is notoriously difficult to disrupt.
Core Discovery: The Synergistic Action of IL-4 and FLT3
To identify a molecular switch capable of reversing this trend, Zhang’s team systematically screened various anti-inflammatory and type 2 cytokines. Their results revealed that interleukin-4 (IL-4) exhibited remarkable potential. Not only did IL-4 specifically suppress inflammation-induced myeloid differentiation in vitro, but it also redirected multipotent progenitors (MPPs) toward the lymphoid lineage.
In-depth mechanistic studies uncovered the underlying regulatory network: in MPPs, the receptor tyrosine kinase FLT3 physically interacts with the IL-4 receptor subunit IL-4Rα. This collaboration dramatically enhances phosphorylation and activation of the downstream molecule STAT6. Engagement of this “IL-4–FLT3–STAT6” signaling axis directly initiates transcriptional programs specific to lymphocyte development.
Animal Studies: From Hematopoietic Reconstitution to Systemic Functional Improvement
In aged mouse models, the translational value of this discovery was confirmed. IL-4 treatment significantly reshaped the composition of MPPs in the bone marrow, restoring their bias toward lymphopoiesis and boosting the output of B and T cells. More importantly, prolonged IL-4 therapy not only improved immune function but also enhanced metabolic profiles, exercise endurance, and even cognitive performance in aged mice. Further transplantation experiments demonstrated that transplanting IL-4–primed hematopoietic stem cells alone was sufficient to transfer these “rejuvenated” phenotypes to recipient animals.
This study not only elucidates a novel mechanism underlying hematopoietic aging but also offers promising new targets and therapeutic strategies for addressing age-related immunodeficiency, chronic inflammatory diseases, and even systemic aging itself. Looking ahead, precise modulation of this pathway may become a powerful tool for slowing the aging process and revitalizing the immune system.
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
